New study recommends switch to volumetric DBS sampling devices to ensure accuracy of PKU monitoring

Sept. 6, 2022
Capitainer’s qDBS card, a device evaluated for performance and ease of integration.

Swedish medtech start-up Capitainer announced that its qDBS card has scored highly in a major new study published in Clinica Chimica Acta on the advantages of volumetric microsampling DBS devices in monitoring of patients with phenylketonuria (PKU).   

The study was necessary according to the authors, because although measurement of dried blood spot phenylalanine (Phe) is central to the monitoring of PKU patients today, the volume and hematocrit (hct) of the blood applied to conventional DBS cards fluctuates and significantly affects analytical results.   

Read full paper here